Ring Therapeutics Announces Two Late Breaker Presentations at the 30th Annual European Society of Gene & Cell Therapy Conference

Ring to present new data on its Anellogy™ platform

The first new class of viral vector in decades – Robust transduction of a variety of cell and tissue types achieved by AnelloVectors

Development of modular manufacturing technology – AnelloBricks – offers a scalable and more versatile approach to addressing limitations in cell-based viral production systems

Cambridge, Mass. September 26, 2023 — Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, today announced two poster presentations at the 30^th Annual European Society of Gene & Cell Therapy (ESGCT) Conference, to be held in Brussels, Belgium from October 24 – 27, 2023. These presentations further demonstrate the potential of Ring’s Anellogy™ platform to successfully overcome some of the largest barriers facing gene therapy – repeated dosing, targeted delivery, and scalable manufacturing.

Presentation details below:

Title: AnelloVectors: a novel functional gene delivery platform based on commensal human anelloviruses demonstrates transduction in multiple cell and tissue types
Board Number:  P003
Lead Author: Joseph Cabral, Ring Therapeutics
Presentation Date and Time: October 25^th, 17:00 -18:15 CEST & October 26^th, 20:30-21:30 CEST

Title: AnelloBricks: a novel, cell-free, in vitro assembled viral vector system based on commensal human anelloviruses offers a highly modular, versatile, and scalable manufacturing platform solution to genetic medicines
Board Number: P004
Lead Author:  Erik Hansen, Ring Therapeutics
Presentation Date and Time:  October 25^th, 18:15 -19:30 CEST & October 26^th, 19:30-20:30 CEST